Skip to main content
. Author manuscript; available in PMC: 2022 Jul 13.
Published in final edited form as: Sci Immunol. 2021 Dec 3;6(66):eabi8635. doi: 10.1126/sciimmunol.abi8635

Fig. 1. A low-dose Ad5-SARS-CoV-2 spike vaccine prime elicits more SARS-CoV-2 CD8+ T cells after boosting compared with an SD prime.

Fig. 1.

(A) Experimental approach for evaluating how the priming dose, either 106 PFU (LD) or 109 PFU (SD), of an Ad5-SARS-CoV-2 spike vaccine affects CD8+ T cell responses after an SD boost dose 4 weeks later in C57BL/6 mice. (B) Representative FACS plots showing the frequencies of SARS-CoV-2–specific CD8+ T cells (Kb VL8+) in PBMCs. (C) Summary of SARS-CoV-2–specific CD8+ T cell responses in PBMCs. (D) Representative FACS plots showing the frequencies of SARS-CoV-2–specific CD8+ T cells (Kb VL8+) in spleen. (E) Summary of SARS-CoV-2–specific CD8+ T cell responses in spleen at day 14 after boost. Data are from two experiments, one with n = 5 mice per group and another with n = 4 to 5 mice per group. All data are shown. Indicated P value was determined by two-way ANOVA in (C) and by unpaired t test in (E). Error bars represent SEM.